SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
1 hedge funds and large institutions have $47 invested in SpringWorks Therapeutics in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $2.18M → $47 (-$2.18M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$2.18M |
SWTX Hedge Fund Activity: Q1 2026 in Review
1 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2026, worth a combined $47 — down 100% from $2.18M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SWTX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $2.18M sold.
- 1 institutional investor held SpringWorks Therapeutics (SWTX) as of Q1 2026, down from 2 in Q4 2025.
- Funds reported $47 of SpringWorks Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new SpringWorks Therapeutics positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest SpringWorks Therapeutics seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $2.18M sold.
Based on aggregated 13F filings for Q1 2026.